Access cutting-edge craniopharyngioma treatment through this clinical trial at a research site in Houston. Study-provided care at no cost to qualified participants.
Access craniopharyngioma specialists in Houston at no cost
This study follows strict safety protocols and ethical guidelines
All study-related craniopharyngioma treatment provided free
ACTEMRA (tocilizumab) is an IL-6 receptor antagonist used for the treatment of adult Rheumatoid Arthritis as well as Polyarticular (PJIA) and Systemic (SJIA) Juvenile Idiopathic Arthritis. In this Phase II, the drug will be used to treat pediatric patients diagnosed with recurrent Adamantinomatous Craniopharyngioma including patients who have undergone surgery and/or radiation therapy.
Sponsor: Nationwide Children's Hospital
Check if you qualify for this craniopharyngioma clinical trial in Houston, TX
If you're searching for craniopharyngioma treatment options in Houston, TX, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Houston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced craniopharyngioma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.